We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GENF Genflow Biosciences Plc

0.05 (3.13%)
05 Dec 2023 - Closed
Delayed by 15 minutes
Genflow Biosciences Investors - GENF

Genflow Biosciences Investors - GENF

Share Name Share Symbol Market Stock Type
Genflow Biosciences Plc GENF London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.05 3.13% 1.65 15:21:41
Open Price Low Price High Price Close Price Previous Close
1.60 1.60 1.65 1.65 1.60
more quote information »
Industry Sector

Top Investor Posts

Top Posts
Posted at 05/12/2023 21:36 by kubera369
Money thanks for all your updates as they are really appreciated I'm just baffled at this SPWhy is Eric not concerned about investors?It was April on that last spike to 5.5p and we have had radio silence from the company since the U.S listing, the share price has just drifted down.
Posted at 17/11/2023 14:30 by moneymunch
I wonder if Jim Mellon's Juvenscene is one of the UK investors Eric has been seeing this week, their Executive Chairman has recently made reference to David Sinclair ( much of his R&D is focused on Sirt6 ) and they've been making and plan to make more investments in the Longevity's hoping Genflow are one of the companies "really doing compelling things right now"....Excitement building on news from Eric on the series of meetings he's had this week with UK investors. Gla :-)

‘We’re at the longevity inflection point – and the explosion is coming.’

Dr Greg Bailey, the Executive Chairman of Juvenescence

To me, being able to invest right now into antiaging and modifying longevity, is exactly at the inflection point that being given the opportunity to invest in generated AI was at three or four years ago – I think it’s gonna have that sort of explosion. We’re seeing it with some of David Sinclair’s work, we’re going to see some astonishing things out of Altos and BioAge. There’s a number of companies that are doing really compelling things right now that are going to explode the space. And I’m not comparing us with the end game – I think generated AI has enormous societal changes and economics associated with it, but just as far as the trajectory of the curve for next two or three years, this, to me, is the time to invest.
Posted at 16/11/2023 16:14 by moneymunch
Lots of potential news in the pipeline line to add significant UPside, expected soon, and should be very interesting to see if Eric has anything to report next week on the series of meetings he's had this week with potential UK investors. The appointment of the Joint Broker last week speaks volumes, hopefully very much needed as the demand for shares goes into overdrive!!! Gla :-)
Posted at 16/11/2023 08:12 by kubera369
Got to be one of the only safest and solid multi multi bagger around hedged by U.S interest = Billionaire investors
Posted at 21/10/2023 14:27 by moneymunch
Hevolution Global Healthspan Summit 29th-30th November 2023

Igniting a Healthy Evolution

Unveiling the Global Healthspan Summit - Together We Thrive! Brought to you by the visionary Hevolution Foundation, this remarkable gathering of thought leaders promises to revolutionize how we view aging and healthspan science.

Where Visionaries Unite

Join us as we assemble the brightest minds, forward-thinking entrepreneurs, and influential stakeholders from across the globe! Scientists & Research Institutions, Innovators & entrepreneurs, investors, corporate leaders, international organizations & non-profits, and dignitaries will come together to facilitate action-based conversations and drive impact around catalyzing international collaboration in the emerging field of healthspan science.

Empowering Action Through Collaboration

No more passive discussions - it’s time for an honest, transformative change! Our Summit is all about action-driven conversations that will fuel groundbreaking research, cutting-edge entrepreneurship, and intelligent investments. Together, we’ll catalyze a global movement that will reshape the future of healthspan science.


We believe now is the decisive moment for decision-makers, investors, visionaries, governments, and researchers to unite. Let’s understand aging processes and elevate the discussion by exploring how to enhance the intersectional factors that promote healthy aging. 


The Global Healthspan Summit is more than just a platform - it’s a catalyst for change! Across two pivotal days, leading minds will convene to discuss the latest insights, facilitating networking and knowledge exchange like never before.
Posted at 14/9/2023 17:40 by moneymunch
The next Longevity Investors Conference will be held in Gstaad on September 27-29 2023

About Longevity Investors Conference (LIC)

The Longevity Investors Conference is bringing together the world's leading longevity key opinion leaders and scientists, institutional and private investors, wealthy private individuals, family offices, and investment funds. The main aim of the event is to discuss the latest trends and opportunities but also to provide relevant insights into the longevity and rejuvenation industry. As an investors-only conference, the event is fully focused on investors.
Posted at 13/8/2023 12:13 by moneymunch
The 2023 Longevity Summit Dublin Conference has announced its first speakers – and tickets are now on sale!

The Summit is on a mission is to recognise emerging research developments to extend human healthspan by gathering together world leading scientists.

To that end, The Longevity Summit Dublin will be a showcase for the most up-to-date research and innovations in the longevity industry and feature keynote presentations by leading experts in the aging field.

This conference, which is running from 17th to 20th August 2023, will feature over 40 global pioneering scientists, researchers and investors, as well as high net-worth investors, all on the same stage and who are all focused on challenging the epidemic of chronic diseases.

Dublin 2023

The premier annual conference of LEV Foundation

Join us August 17th – 20th 2023

Join the   ;Global Longevity
and Rejuvenation community
in  Dublin.

Network with leading figures around the world, build relationships with the longevity science industry and community, and learn about the latest emerging research. Longevity Summit Dublin is a must see for all science enthusiasts and all health enthusiasts.

Key note speakers include Vera Gorbunova- University of Rochester.
Posted at 08/8/2023 15:53 by kubera369
Join Us For Our 6th Annual ConferenceOn August 10-11, 2023, we will be holding our sixth annual Ending Age-Related Diseases (EARD) conference to bring entrepreneurs, investors, pharma and biotech companies, researchers, and government organizations together. Fostering the exchange of information and encouraging cooperation between the various parts of the industry is the goal of our non-profit organization.The event will be held at the Capitale building in New York City, and there is also an option to join the conference online. The doors open at 9am Eastern time, event starts 10am and runs until 5:30pm Eastern time.This year, not only are we bringing leaders in longevity research together, we are also including experts from the decentralized science (DeSci) movement. DeSci is an open science movement that aims to build public infrastructure for funding, creating, reviewing, crediting, storing, and disseminating scientific knowledge fairly and equitably.DeSci is the next evolution of crowdfunding, and because most of it is rooted in blockchain, it has attracted support from members of the cryptocurrency community who also want longer and healthier lives. Solving aging is going to take large-scale funding and the DeSci movement makes raising those funds more likely using blockchain technology that is free from the constraints of the traditional grant system.Bring on 10p after this event Based in New York with heavy industry hitters attending With the lack of free float and New U.S investors/institutions coming on board - the patience is about to be paid off.I'm taking a nice lump tomorrow to add to my existing holding GLA
Posted at 20/6/2023 13:47 by jmoo1
Looks like this might drum up a bit of interest / exposure this week: OTC DISCLOSURE & NEWS SERVICE
Genflow Bioscineces to Present at the Life Science Investors Forum June 22nd
Press Release | 06/20/2023
LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Genflow Biosciences (OTCQB:GENFF), a biotechnology company based in the UK, focused on longevity, today announced that Dr. Eric Leire, CEO, will present live at the Life Science Investors Forum, hosted by, on June 22nd , 2023.

DATE: June 22nd ,2023
TIME: 11:00am
LINK: [...]
Available for 1x1 meetings: June 23, 26 and 27.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
Posted at 13/6/2023 06:02 by moneymunch
RNS Number : 4646C
Genflow Biosciences PLC
13 June 2023

Genflow Biosciences Plc

("Genflow" or "the Company")

Anti-Ageing Company, Genflow Biosciences, Announces Listing on OTCQB Venture Market

in addition to its LSE Main Market Listing

Genflow has 3 Gene Therapies in Development Seeking to Treat NASH and Werner Syndrome

Genflow Biosciences Plc ("Genflow" or "the Company") is pleased to announce that, after a successful application process, its Ordinary Shares ("Ordinary Shares") begin trading on the OTCQB Venture Market in the United States ("US") today under the symbol GENFF. Genflow will continue to trade on the London Stock Exchange ("LSE") Main Market under the symbol GENF, and, importantly, the onboarding to this additional U.S. securities trading platform does not involve any capital raise. The new U.S. trading facility expands access to a broader pool of investors and enables investors in the United States to trade during U.S. trading hours and in U.S. dollars.

Eric Leire, CEO of Genflow, expressed his excitement about this significant achievement, stating, "We are thrilled to announce that Genflow Biosciences has been admitted to trading on the OTCQB Venture Market in the United States. This move not only expands our reach to a larger investor base and has the potential to enhance liquidity for our shares, but also reinforces our unwavering commitment to our primary listing on the prestigious London Stock Exchange."

Tamara Joseph, Chair of the Board, also expressed her enthusiasm on behalf of the Board of Directors, saying, "Genflow is developing gene therapies that could address an important source of many global illnesses: aging. As the Company moves into Phase I/II clinical trials to treat potentially the orphan condition Werner Syndrome, which causes premature aging, and NASH, a liver disease that affects an estimated 35 million people around the world, it is the right time to retain our London Stock Exchange listing while adding easier access for US investors."

Further information on Genflow's application and the OTCQB market is below:

As a Foreign Private Issuer, Genflow's admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies. This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that certain information made public or distributed under home market regulations is made publicly available on the Company's website or other electronic information delivery system in English. Thus, the Company will have no additional reporting obligations and incur minimal ongoing costs; admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies.

This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. Under this exemption, the Company must ensure that information made public or distributed under its home market regulations is made available to the public on its website or another electronic information delivery system in English. Consequently, Genflow will have no additional reporting obligations and will incur minimal ongoing costs compared to traditional major exchanges.

As a verified market, the OTCQB offers transparent trading for companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process.

The cross-trading facility is provided through OTC Markets Group Inc., located in New York. OTC Markets operates the world's largest electronic interdealer quotation system for US broker-dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Online brokers such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade all offer OTCQB trades. US investors can find real-time quotes, market information and access current company news and developments on a BSF page on the OTC Markets website at

Genflow appointed the corporate securities law firm Galanopoulos & Company as its OTCQB Sponsor to support its onboarding to the OTCQB Venture Market.

Additional information about the OTCQB market can be found at:

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |